Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease.

Literature DB >> 4155692

Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease.

Abstract

The faecal flora of 21 patients with proctocolitis and five patients with Crohn's disease of the large bowel was examined both while sulphasalazine was being administered and during control periods. Patients with proctocolitis and Crohn's disease who were not receiving sulphasalazine had a similar flora which did not differ in any way from the normal. The effect of sulphasalazine was to decrease the numbers of opalescent-negative clostridia, enterobacteria, and total non-sporing anaerobes. It is suggested that this antibacterial effect of sulphasalazine, which has not been previously demonstrated, may be related to the beneficial effects of this drug in proctocolitis and should be investigated further.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1974 PMID： 4155692 PMCID： PMC1413081 DOI： 10.1136/gut.15.12.960

Source DB: PubMed Journal: Gut ISSN： 0017-5749 Impact factor: 23.059

18 in total

1. Faecal flora of patients with ulcerative colitis during treatment with salicylazosulphapyridine.

Authors: E M Cooke
Journal: Gut Date: 1969-07 Impact factor: 23.059

2. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.

Authors: M A Peppercorn; P Goldman
Journal: J Pharmacol Exp Ther Date: 1972-06 Impact factor: 4.030

3. Absorption, metabolism, and excretion of salicylazosulfapyridine in man.

Authors: H Schröder; D E Campbell
Journal: Clin Pharmacol Ther Date: 1972 Jul-Aug Impact factor: 6.875

4. Transport and storage of faeces for bacteriological examination.

Authors: J S Crowther
Journal: J Appl Bacteriol Date: 1971-06

5. Bacteria and aetiology of cancer of large bowel.

Authors: M J Hill; B S Drasar; G Hawksworth; V Aries; J S Crowther; R E Williams
Journal: Lancet Date: 1971-01-16 Impact factor: 79.321

6. Metabolism of salicylazosulfapyridine in healthy subjects and in patients with ulcerative colitis. Effects of colectomy and of phenobarbital.

Authors: H Schröder; R M Lewkonia; D A Price Evans
Journal: Clin Pharmacol Ther Date: 1973 Sep-Oct Impact factor: 6.875

7. Azo reduction of salicyl-azo-sulphapyridine in germ-free and conventional rats.

Authors: H Schröder; B E Gustafsson
Journal: Xenobiotica Date: 1973-04 Impact factor: 1.908

8. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

Authors: A S Dissanayake; S C Truelove
Journal: Gut Date: 1973-12 Impact factor: 23.059

9. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.

Authors: K M Das; M A Eastwood; J P McManus; W Sircus
Journal: Gut Date: 1973-08 Impact factor: 23.059

10. Oral nanotherapeutics: effect of redox nanoparticle on microflora in mice with dextran sodium sulfate-induced colitis.

Authors: Long Binh Vong; Toru Yoshitomi; Kazuya Morikawa; Shinji Saito; Hirofumi Matsui; Yukio Nagasaki
Journal: J Gastroenterol Date: 2013-05-29 Impact factor: 7.527

Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease.

1. Faecal flora of patients with ulcerative colitis during treatment with salicylazosulphapyridine.

2. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.

3. Absorption, metabolism, and excretion of salicylazosulfapyridine in man.

4. Transport and storage of faeces for bacteriological examination.

5. Bacteria and aetiology of cancer of large bowel.

6. Metabolism of salicylazosulfapyridine in healthy subjects and in patients with ulcerative colitis. Effects of colectomy and of phenobarbital.

7. Azo reduction of salicyl-azo-sulphapyridine in germ-free and conventional rats.

8. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

9. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.

10. Properties of strains of Escherichia coli carried in different phases of ulcerative colitis.

1. Plasma and synovial fluid concentrations of sulphasalazine and two of its metabolites in rheumatoid arthritis.

Review 2. Escherichia coli and ulcerative colitis.

3. Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease.

Review 4. Inflammatory bowel disease as a model for translating the microbiome.

5. Rheumatoid arthritis and the gut.

6. Sulphasalazine in rheumatoid arthritis: an old drug revived.

7. Functional suppressor T cell activity in Crohn's disease and the effects of sulphasalazine.

8. The effect of intestinal bacteria adherence on drug diffusion through solid films under stationary conditions.

Review 9. Idiopathic Inflammation Bowel Disease: is there a role for immunological mechanisms in etiopathogenesis?

10. Oral nanotherapeutics: effect of redox nanoparticle on microflora in mice with dextran sodium sulfate-induced colitis.